Patents Assigned to Genentech
  • TREATMENT METHOD
    Publication number: 20110262436
    Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer.
    Type: Application
    Filed: October 14, 2009
    Publication date: October 27, 2011
    Applicant: Genentech, Inc.
    Inventors: Brendan C. Bender, Steve Eppler, Priti Hegde, Nelson L. Jumbe, Mark Merchant, Amy C. Peterson, Arthur E. Reyes, II, Hong Xiang
  • ANTI-HEPSIN ANTIBODIES AND METHODS USING SAME
    Publication number: 20110262452
    Abstract: The invention provides hepsin antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: October 21, 2010
    Publication date: October 27, 2011
    Applicant: Genentech, Inc.
    Inventors: Rajkumar Ganesan, Daniel Kirchhofer, Paul M. Moran, Yingnan Zhang
  • PROSTATE STEM CELLS AND USES THEREOF
    Publication number: 20110262465
    Abstract: Prostate stem cells and prostate cancer stem cells and their use in treating prostate cancer and regenerating prostate tissue are disclosed.
    Type: Application
    Filed: October 21, 2009
    Publication date: October 27, 2011
    Applicant: Genentech, Inc.
    Inventors: Wei-Qiang Gao, Leisa Johnson, Kevin G. Leong
  • Protein purification
    Patent number: 8044017
    Abstract: A method for purifying a polypeptide by ion exchange chromatography is described in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants.
    Type: Grant
    Filed: September 10, 2003
    Date of Patent: October 25, 2011
    Assignee: Genentech, Inc.
    Inventors: Jefferson C. Emery, Paul J. McDonald, Rhona O'Leary
  • ANTI-LRP6 ANTIBODIES
    Publication number: 20110256127
    Abstract: The invention provides anti-LRP6 antibodies and methods of using the same. A particular aspect of the invention provides for bispecific anti-LRP6 antibodies that inhibit signaling by multiple Wnt isoforms.
    Type: Application
    Filed: March 23, 2011
    Publication date: October 20, 2011
    Applicant: Genentech, Inc.
    Inventors: Eric Bourhis, Tim Cao, Rick Carano, Andrea Cochran, Mike Costa, Venita DeAlmeida, James Ernst, Yan Gong, Rami Hannoush, Paul Polakis, Bonnee Rubinfeld, Mark Solloway, Yan Wu
  • Modulation of Axon Degeneration
    Publication number: 20110256150
    Abstract: The invention relates generally to treatment of neurological disorders and nervous system injuries. The invention specifically provides methods of using modulators of particular target proteins to modulate degeneration of neurons or portions thereof, such as axons.
    Type: Application
    Filed: October 22, 2009
    Publication date: October 20, 2011
    Applicant: Genentech, Inc.
    Inventors: Ryan Watts, Mark Chen, Joseph Wesley Lewcock, Christine Pozniak, Arundhati Sengupta-Ghosh
  • ANTI-POLYUBIQUITIN ANTIBODIES AND METHODS OF USE
    Publication number: 20110256133
    Abstract: The invention provides anti-polyubiquitin antibodies and methods of using the same.
    Type: Application
    Filed: April 14, 2011
    Publication date: October 20, 2011
    Applicant: GENENTECH, INC.
    Inventors: VISHVA DIXIT, ROBERT F. KELLEY, MARISSA L. MATSUMOTO
  • NEUROPILIN ANTAGONISTS
    Publication number: 20110256146
    Abstract: Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Application
    Filed: June 30, 2011
    Publication date: October 20, 2011
    Applicant: Genentech, Inc.
    Inventors: Ryan J. Watts, Yan Wu
  • 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS
    Publication number: 20110251181
    Abstract: Compounds of Formula I are useful for inhibiting AKT protein kinases. Methods using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. Formula (I).
    Type: Application
    Filed: January 9, 2009
    Publication date: October 13, 2011
    Applicants: Genentech, Inc., Array BoPharma Inc.
    Inventors: Anna Banka, Josef R. Bencsik, James Blake, Martin Hentermann, Stephen T. Schlachter, Eli M. Wallace, Rui Xu
  • Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
    Patent number: 8034342
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Grant
    Filed: August 28, 2009
    Date of Patent: October 11, 2011
    Assignee: Genentech, Inc.
    Inventors: Jian Chen, Ellen Filvaroff, Sherman Fong, Dorothy French, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Kenneth J. Hillan, Sarah G. Hymowitz, Hanzhong Li, James Pan, Melissa A. Starovasnik, Daniel Tumas, Menno Van Lookeren, Richard Vandlen, Colin K. Watanabe, P. Mickey Williams, William I. Wood, Daniel G. Yansura
  • PREDICTING RESPONSE TO A HER INHIBITOR
    Publication number: 20110245103
    Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
    Type: Application
    Filed: June 1, 2011
    Publication date: October 6, 2011
    Applicants: Genentech, Inc., Hoffmann-La Roche. Inc.
    Inventors: Lukas C. Amler, Merrill Birkner, Chin-Yu Lin, Joachim Moecks, Andreas Strauss
  • APO-2 ligand/trail formulations
    Publication number: 20110245185
    Abstract: The inventions include Apo2L/TRAIL formulations and methods of using such formulations. Lyophilized and crystal formulations of Apo-2L/TRAIL which are stable and have improved Apo2L/TRAIL trimer formation are provided. Methods of making Apo-2L/TRAIL formulations, as well as devices and kits containing such formulations are also provided.
    Type: Application
    Filed: October 21, 2010
    Publication date: October 6, 2011
    Applicant: Genentech, Inc.
    Inventors: Heather Flores, Tanya P. Lin, Timothy C. Matthews, Roger Pai, Zahra Shahrokh
  • PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
    Publication number: 20110245230
    Abstract: The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: June 14, 2011
    Publication date: October 6, 2011
    Applicants: Array BioPharma Inc., Genentech, Inc.
    Inventors: Ian S. Mitchell, James F. Blake, Rui Xu, Nicholas C. Kallan, Dengming Xiao, Keith Lee Spencer, Josef R. Bencsik, Eli M. Wallace, Stephen T. Schlachter, Anna L. Banka, Jun Liang, Brian Safina, Jun Li, Christine Chabot
  • PREDICTING RESPONSE TO A HER INHIBITOR
    Publication number: 20110246399
    Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
    Type: Application
    Filed: June 1, 2011
    Publication date: October 6, 2011
    Applicants: Genentech, Inc., Hoffmann-La Roche, Inc.
    Inventors: LUKAS C. AMLER, Merrill Birkner, Chin-Yu Lin, Joachim Moecks, Andreas Strauss
  • Anti-hedgehog antibodies
    Patent number: 8030454
    Abstract: The invention relates to anti-hedgehog antibodies, their use in the detection of hedgehog expression in tissue, and to the use of such detection in the treatment of cancer.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: October 4, 2011
    Assignee: Genentech, Inc.
    Inventor: Suzanna J. Scales
  • Nucleic acid encoding DR5 antibodies and uses thereof
    Patent number: 8030023
    Abstract: The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.
    Type: Grant
    Filed: October 10, 2006
    Date of Patent: October 4, 2011
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Avi J. Ashkenazi
  • DR5 antibodies and articles of manufacture containing same
    Patent number: 8029783
    Abstract: The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.
    Type: Grant
    Filed: January 30, 2006
    Date of Patent: October 4, 2011
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Avi J. Ashkenazi
  • CDR-REPAIRED ANTIBODIES
    Publication number: 20110237779
    Abstract: The present application concerns restoring antigen binding during humanization of antibodies through the selection of repaired hypervariable regions rather than through framework changes.
    Type: Application
    Filed: November 16, 2010
    Publication date: September 29, 2011
    Applicant: Genentech, Inc.
    Inventor: Mark S. Dennis
  • ANTIBODY FORMULATION
    Publication number: 20110226650
    Abstract: The invention provides a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, optionally, not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.0 to about 6.0, and an optional surfactant, methods for making such a formulation, and methods of using such a formulation.
    Type: Application
    Filed: December 20, 2010
    Publication date: September 22, 2011
    Applicant: Genentech, Inc.
    Inventors: Yatin R. Gokarn, Timothy J. Kamerzell, Megan Li, Mary Cromwell, Hong Liu
  • HUMAN GROWTH HORMONE AQUEOUS FORMULATION
    Publication number: 20110230408
    Abstract: A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations.
    Type: Application
    Filed: June 1, 2011
    Publication date: September 22, 2011
    Applicant: Genentech, Inc.
    Inventors: Barbara H. O'Connor, James Q. Oeswein